Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of inactivated VZV vaccine (V212) in adult autologous hematopoietic cell transplant recipients
NL-OMON40043Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Aug 2011
- Modality
- Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in herpes zoster (HZ) comparing V212 vaccine with Placebo (2 arms). Primary endpoints: Safety and tolerability of V212 and Development of herpes zoster. Started Aug 2011; status: active, not recruiting.
02
Drugs
zoster vaccine live
03
Conditions
herpes zoster (HZ)
Beyond the preview
Go deeper on NL-OMON40043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40043.